Literature DB >> 24708263

Three-dimensional tumor volume and serum alpha-fetoprotein are predictors of hepatocellular carcinoma recurrence after liver transplantation: refined selection criteria.

Samy Kashkoush1, Walid El Moghazy, Toshiyasu Kawahara, Boris Gala-Lopez, Christian Toso, Norman M Kneteman.   

Abstract

Total tumor volume (TTV), as a better predictor of hepatocellular carcinoma (HCC) recurrence after liver transplant, has been explored by our center. Some tumors are not typically spherical but rather ellipsoid or spheroid, and calculating their TTV based on one dimension only may overestimate their volume and exclude them from candidacy for transplantation. Our aim was to study the actual tumor volume (ATV) calculated using the ellipsoid formula and assess its impact on recurrence. HCC patients transplanted between 1990 and 2010 at University of Alberta Hospital were analyzed. Tumor volumes were calculated using both formulas: [(4/3) πr(3)] (r = max. radius) and [(4/3) πabc] (a, b, c = the 3 radiuses). A total of 115 patients were included with a mean follow-up of 4.99 ± 4.23 yr. Five-yr recurrence-free survival was 79.8%. Univariate analysis for predictors of recurrence included: maximum tumor diameter, ATV, TTV, and alpha-fetoprotein (AFP) ≥ 400 ng/mL. Multivariate analysis showed that ATV and AFP ≥ 400 ng/mL were the only predictors of recurrence. Combining both variables provides better predication of recurrence with accuracy that exceeds 80%. Three-dimensional calculation of tumor volume is of critical importance for the group of patients with ellipsoid tumors where volumes are overestimated with the spherical formula and could lead to inappropriate exclusion from transplant.
© 2014 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  alpha-fetoprotein; hepatocellular carcinoma; liver transplantation; recurrence; tumor volume

Mesh:

Substances:

Year:  2014        PMID: 24708263     DOI: 10.1111/ctr.12373

Source DB:  PubMed          Journal:  Clin Transplant        ISSN: 0902-0063            Impact factor:   2.863


  15 in total

1.  Pre-transplant alpha-fetoprotein is associated with post-transplant hepatocellular carcinoma recurrence mortality.

Authors:  Nadim Mahmud; Binu John; Tamar H Taddei; David S Goldberg
Journal:  Clin Transplant       Date:  2019-06-25       Impact factor: 2.863

2.  Risk Factors and Center-Level Variation in Hepatocellular Carcinoma Under-Staging for Liver Transplantation.

Authors:  Nadim Mahmud; Maarouf A Hoteit; David S Goldberg
Journal:  Liver Transpl       Date:  2020-08       Impact factor: 5.799

Review 3.  Contribution of alpha-fetoprotein in liver transplantation for hepatocellular carcinoma.

Authors:  Bérénice Charrière; Charlotte Maulat; Bertrand Suc; Fabrice Muscari
Journal:  World J Hepatol       Date:  2016-07-28

Review 4.  Advances in predicting the prognosis of hepatocellular carcinoma recipients after liver transplantation.

Authors:  Li-Ying Wang; Shu-Sen Zheng
Journal:  J Zhejiang Univ Sci B       Date:  2018-07       Impact factor: 3.066

5.  The allosteric AKT inhibitor, MK2206, decreases tumor growth and invasion in patient derived xenografts of endometrial cancer.

Authors:  Abigail Winder; Kenji Unno; Yanni Yu; John Lurain; J Julie Kim
Journal:  Cancer Biol Ther       Date:  2017-11-27       Impact factor: 4.742

Review 6.  Multidisciplinary perspective of hepatocellular carcinoma: A Pacific Northwest experience.

Authors:  Matthew M Yeh; Raymond S Yeung; Smith Apisarnthanarax; Renuka Bhattacharya; Carlos Cuevas; William P Harris; Tony Lim Kiat Hon; Siddharth A Padia; James O Park; Kevin M Riggle; Sayed S Daoud
Journal:  World J Hepatol       Date:  2015-06-18

7.  Screening for hepatocellular carcinoma and cholangiocarcinoma: Can biomarkers replace imaging?

Authors:  Maria E Lozada; Roongruedee Chaiteerakij; Lewis R Roberts
Journal:  Curr Hepatol Rep       Date:  2015-06

8.  3D Quantitative tumour burden analysis in patients with hepatocellular carcinoma before TACE: comparing single-lesion vs. multi-lesion imaging biomarkers as predictors of patient survival.

Authors:  Florian N Fleckenstein; Rüdiger E Schernthaner; Rafael Duran; Jae Ho Sohn; Sonia Sahu; Yan Zhao; Bernd Hamm; Bernhard Gebauer; MingDe Lin; Jean-François Geschwind; Julius Chapiro
Journal:  Eur Radiol       Date:  2016-01-13       Impact factor: 5.315

9.  Differences in Posttransplant Hepatocellular Carcinoma Recurrence by Etiology of Liver Disease.

Authors:  Nadim Mahmud; Abraham Shaked; Kim M Olthoff; David S Goldberg
Journal:  Liver Transpl       Date:  2019-03       Impact factor: 5.799

10.  Multiplication of Tumor Volume by Two Tumor Markers Is a Post-Resection Prognostic Predictor for Solitary Hepatocellular Carcinoma.

Authors:  Shin Hwang; Gi-Won Song; Young-Joo Lee; Ki-Hun Kim; Chul-Soo Ahn; Deok-Bog Moon; Tae-Yong Ha; Dong-Hwan Jung; Gil-Chun Park; Sung-Gyu Lee
Journal:  J Gastrointest Surg       Date:  2016-06-16       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.